Financings Of The Fortnight: Tough To Diagnose Meaning Of Genmark's IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
The small diagnostic firm's reverse merger followed by a smallish IPO might be a harbinger of financings to come. Or not.
You may also be interested in...
FDA Aims To Clear Hurdles For Severe Bleeding Products With Workshop, Advisory Committee
Community consent and other controversial practices involved with enrolling trauma patients in clinical trials will be addressed.
FDA Aims To Clear Hurdles For Severe Bleeding Products With Workshop, Advisory Committee
Community consent and other controversial practices involved with enrolling trauma patients in clinical trials will be addressed.
Exelixis Stays The Course Under New Leadership of Michael Morrissey
As the R&D chief transitions to CEO, he sees no huge strategic shifts for Exelixis, though it "has had a tough six months."